Director, Clinical Science
Celldex Therapeutics
Director, Clinical Science
Celldex Therapeutics
Develops antibody-based therapies targeting inflammatory diseases
Celldex is pioneering new horizons in immunology to deliver life-changing therapies. We are relentless in our pursuit of novel antibody-based treatments that engage the human immune system and directly affect critical pathways to improve the lives of patients with allergic, inflammatory and autoimmune disorders. We have built a culture where innovative and talented people thrive—focusing a significant effort on attracting and retaining passionate and motivated employees who want to play a role in helping people with serious health conditions and who see this effort as personally rewarding. In our highly entrepreneurial environment, employees are empowered and the opportunity for professional development occurs every day.
The Director, Clinical Science is a strategic scientific leader responsible for clinical study design, clinical data review, and execution of clinical development programs supporting innovative therapies. This individual will play a central role in translating scientific and medical insights into robust clinical studies and development strategies, while leading the interpretation of clinical data to inform key program decisions.
Working closely with Clinical Science physicians, Clinical Operations, Data Management, Biostatistics, Regulatory Affairs, Medical Writing, Biomarker/Translational Research, Pharmacovigilance, and Medical Affairs, the Director, Clinical Science will provide leadership across all phases of development, with particular emphasis on protocol development and study design, data review and interpretation, and data-driven decision making.
Clinical Study Design and Development Strategy
Clinical Data Review and Interpretation
Clinical Trial Execution and Scientific Oversight
Regulatory and Scientific Contributions
Cross-Functional Leadership
Develops antibody-based therapies targeting inflammatory diseases
Celldex Therapeutics develops antibody-based therapies for inflammatory, allergic, and autoimmune diseases, focusing on mast cell biology. Its lead program barzolvolimab is a humanized monoclonal antibody that inhibits KIT, reducing mast cell activity and inflammation; its pipeline includes other antibodies designed to engage the immune system or modulate disease pathways. The company leverages partnerships and licensing in addition to developing its own therapies to create a breadth of programs in its target areas. Its goal is to deliver therapies that lessen inflammation and autoimmune activity by targeting mast cells and related signaling pathways.
Explore more opportunities at Celldex Therapeutics